Oncology Cancer Drugs Market

Oncology (1985-2016) – 157 cancer drugs  – Ranking and detailed regulatory approval profiles” is a comprehensive drug ranking and profiling report that ranks cancer drugs based on total approvals and unique approvals received in US, Europe and Japan. It provides the regulatory approval details of each drug for the past 30 years (1985-2016) in both the tabular and (an interesting) infographic formats. Additionally, the basic drug-specific information such as first approvals, breakthrough, orphan designations, black box warnings, etc., is also presented along with negative developments of drugs recalled, discontinued and withdrawn.

We have screened and segmented 157 drugs (from a list of 250 approved cancer drugs) based on the criteria of at least one new or additional approval in the past decade. This report gives detailed information about these drugs and their approval histories from all the three regulatory bodies, namely, the US-based United States Food and Drugs Authority (USFDA), Europe-based European Medicines Agency (EMA) and Japan-based Pharmaceuticals and Medical Devices Agency (PMDA). 

The report is divided into two broader sections (Ranking and Drug Profiles) and several sub-sections. We have sequenced 157 drugs into six segments based on total number of approvals: Segment A –  25+ approvals; Segment B – 15 to 24 approvals; Segment C – 10 to 14 approvals; Segment D – 5 to 9 approvals; Segment E – 2 to 4 approvals; Segment F –  only one approval. Similarly, drugs are ranked in various segments based on unique approvals. Each drug in the drug profile section is described in the following three parts: Part 1 – basic information, Part 2 – approval timeline infographic and Part 3 – approval history tables.